射血分数保留的心力衰竭中甲状腺素转运蛋白淀粉样心肌病的患病率
这项基于社区的队列研究在1235例HFpEF伴心室壁增厚的患者中评估ATTR-CM患病率,常规临床诊断仅识别1.3%,而系统筛查的286例中患病率为6.3%,且随年龄增长而升高,在老年男性中尤为突出。结果表明系统评估可提高ATTR-CM诊断率,为HFpEF提供治疗相关的表型分型。
要点
- HFpEF伴心室壁增厚患者中,临床常规诊断的ATTR-CM患病率仅1.3%。
- 系统筛查可使ATTR-CM患病率升至6.3%,90岁以上人群达21%。
核心结论
- 在社区HFpEF伴心室壁增厚患者中,ATTR-CM在相当数量病例中存在,尤其在老年男性中。
- 系统评估可提高ATTR-CM诊断率,从而为HFpEF提供治疗相关的表型分型。
研究设计与样本
- 基于社区的队列研究,纳入1235例连续HFpEF患者,来自明尼苏达州东南部。
- 关键入组标准包括确诊HF、年龄≥60岁、射血分数≥40%及心室壁厚度≥12 mm。
- 社区筛查队列为286例接受锝-99m焦磷酸盐闪烁扫描的患者,筛查时间为2017年10月5日至2020年3月9日。
主要发现
- 在1235例社区队列(未筛查组)中,16例(1.3%;95% CI,0.7%-2.1%)有临床识别的ATTR-CM。
- 未筛查组中男性患病率2.5%(95% CI,1.4%-4.0%),女性0%(95% CI,0.0%-0.6%)。
- 在286例社区筛查队列中,18例(6.3%;95% CI,3.8%-9.8%)患有ATTR-CM。
- 筛查队列患病率随年龄从60-69岁的0%增至90岁及以上的21%(P < .001)。
- 调整年龄后,男性149例中15例(10.1%;95% CI,5.7%-16.1%)患病,女性137例中3例(2.2%;95% CI,0.4%-6.3%)患病(P = .002)。
临床怎么用
- 对HFpEF伴心室壁增厚的患者,尤其老年男性,应考虑系统筛查ATTR-CM以指导治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Heart failure (HF) with preserved ejection fraction (HFpEF) is common, is frequently associated with ventricular wall thickening, and has no effective therapy. Transthyretin amyloid cardiomyopathy (ATTR-CM) can cause the HFpEF clinical phenotype, has highly effective therapy, and is believed to be underrecognized. OBJECTIVE: To examine the prevalence of ATTR-CM without and with systematic screening in patients with HFpEF and ventricular wall thickening. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study assessed ATTR-CM prevalence in 1235 consecutive patients in southeastern Minnesota with HFpEF both without (prospectively identified cohort study) and with (consenting subset of cohort study, n = 286) systematic screening. Key entry criteria included validated HF diagnosis, age of 60 years or older, ejection fraction of 40% or greater, and ventricular wall thickness of 12 mm or greater. In this community cohort of 1235 patients, 884 had no known ATTR-CM, contraindication to technetium Tc 99m pyrophosphate scanning, or other barriers to participation in the screening study. Of these 884 patients, 295 consented and 286 underwent scanning between October 5, 2017, and March 9, 2020 (community screening cohort). EXPOSURES: Medical record review or technetium Tc 99m pyrophosphate scintigraphy and reflex testing for ATTR-CM diagnosis. MAIN OUTCOMES AND MEASURES: The ATTR-CM prevalence by strategy (clinical diagnosis or systematic screening), age, and sex. RESULTS: A total of 1235 patients participated in the study, including a community cohort (median age, 80 years; interquartile range, 72-87 years; 630 [51%] male) and a community screening cohort (n = 286; median age, 78 years; interquartile range, 71-84 years; 149 [52%] male). In the 1235 patients in the community cohort without screening group, 16 patients (1.3%; 95% CI, 0.7%-2.1%) had clinically recognized ATTR-CM. The prevalence was 2.5% (95% CI, 1.4%-4.0%) in men and 0% (95% CI, 0.0%-0.6%) in women. In the 286 patients in the community screening cohort, 18 patients (6.3%; 95% CI, 3.8%-9.8%) had ATTR-CM. Prevalence increased with age from 0% in patients 60 to 69 years of age to 21% in patients 90 years and older (P < .001). Adjusting for age, ATTR-CM prevalence differed by sex, with 15 of 149 men (10.1%; 95% CI, 5.7%-16.1%) and 3 of 137 women (2.2%; 95% CI, 0.4%-6.3%) having ATTR-CM (P = .002). CONCLUSIONS AND RELEVANCE: In this cohort study based in a community-based setting, ATTR-CM was present in a substantial number of cases of HFpEF with ventricular wall thickening, particularly in older men. These results suggest that systematic evaluation can increase the diagnosis of ATTR-CM, thereby providing therapeutically relevant phenotyping of HFpEF.
引用
- AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021. PMID: 34431962. doi:10.1001/jamacardio.2021.3070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。